Last reviewed · How we verify

NCT05209906

An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain

Completed Last updated 23 August 2022
What this trial tests

trial testing Fentanyl Buccal Soluble Film in Cancer Pain in 37 participants. Completed in 15 August 2022.

Timeline
6 November 2019
Primary endpoint
15 August 2022
15 August 2022

Quick facts

Lead sponsorMackay Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment37
Start date6 November 2019
Primary completion15 August 2022
Estimated completion15 August 2022
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Mackay Memorial Hospital

Who can join

Adults 20 to 80, any sex, with Cancer Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open-label, single arm, observation study, to assess the efficacy and safety of proportional doses of Painkyl® in patients with breakthrough cancer pain.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.
    Chiang YH, Lien CT, Su WH, Yen TY, et al · · 2024 · cited 1× · PMID 38877477 · DOI 10.1186/s12904-024-01483-7

Verify or expand the search:

Other recruiting trials for Cancer Pain

Currently open trials in the same condition.

Other Mackay Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05209906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing